A recent study published in the Journal of Psychopharmacology reveals that maintenance ketamine treatment is both safe and effective for patients with treatment-resistant generalized anxiety disorder (GAD) and social anxiety disorder (SAD). Conducted over three months, the study involved 20 patients who received weekly doses of ketamine. Results indicated a significant decrease in anxiety symptoms, with around a 50% reduction in Fear Questionnaire and Hamilton Anxiety ratings shortly after dosing. Additionally, patients reported improvements in social and work functioning. The study suggests that maintenance ketamine treatment could be a viable option for those with treatment-resistant GAD/SAD.